Lung cancer in women: Differences in epidemiology, biology, histology, and treatment outcomes

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 6, 2013, Pages 792-801

  Rivera, M Patricia ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

cancer of the lung in women; DNA repair; estrogen receptor; growth factor receptors; hormonal factors; lung cancer in women; non small cell lung cancer; sex differences in lung cancer; small cell lung cancer

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FULVESTRANT; GASTRIN RELEASING PEPTIDE; GEFITINIB; GLUTATHIONE TRANSFERASE; GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN P53; TAMOXIFEN; TOBACCO SMOKE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN METASTASIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CAUSE OF DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DISEASE ASSOCIATION; DNA ADDUCT; DNA REPAIR; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; GENE MUTATION; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; MENOPAUSE; METABOLIC ACTIVATION; ONCOGENE K RAS; OVERALL SURVIVAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SEX DIFFERENCE; SMOKING; SMOKING HABIT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UNITED STATES; UTERINE CERVIX CANCER;

CYTOCHROME P-450 ENZYME SYSTEM; DNA REPAIR; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; RECEPTORS, GROWTH FACTOR; RISK FACTORS; SEX FACTORS; SMOKING; TREATMENT OUTCOME; UNITED STATES;

EID: 84888321093     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1358550     Document Type: Article

References (112)

1. Giovino G. A. Epidemiology of tobacco use in the United States. Oncogene: 2002; 21 48 7326 7340 (Pubitemid 35314510)
2. Fiore M. C., Novotny T. E., Pierce J. P., Hatziandreu E. J., Patel K. M., Davis R. M. Trends in cigarette smoking in the United States. The changing influence of gender and race. JAMA: 1989; 261 1 49 55 (Pubitemid 19026381)
3. World Health Organization (WHO) Women and Health: Today's Evidence, Tomorrow's Agenda. Geneva, Switzerland World Health Organization: 2009
4. Mackay J., Eriksen M. P., Shafey O. The Tobacco Atlas. 2nd ed. Atlanta, GA American Cancer Society: 2006
5. Centers for Disease Control and Prevention (CDC) Current cigarette smoking among adults in the United States 2011. MMWR Morb Mortal Wkly Rep: 2012; 61 44 889 894
6. Eaton D. K., Kann L., Kinchen S., et al. Centers for Disease Control and Prevention (CDC). Youth risk behavior surveillance-United States, 2011. MMWR Surveill Summ: 2012; 61 4 1 162
7. Cigarettes smoking: Slight fall in smoking prevalence [database on the Internet]. www.statistics.gov.uk/hub/health-social-case/health-of-the-population United Kingdom Office of National Statistics, 2006 [cited April 15, 2013]
8. Center for Disease Control and Prevention (CDC) www.who.int/tabacco/ surveillance/2009-gats-report-phillipines Global adult tobacco survey: Philippines Data; 2009. [cited April 15, 2013]
9. World Health Organization www.who.int/tabacco/wntd/2010/announcement World No Tobacco Day 2010: Theme: Gender and tobacco with an emphasis on marketing to women. Geneva, Switzerland World Health Organization: 2009; [cited May 2 2012]
10. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin: 2013; 63 1 11 30
11. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer: 2013; 49 6 1374 1403
12. Malvezzi M., Bertuccio P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2013. Ann Oncol: 2013; 24 3 792 800
13. Thun M. J., Carter B. D., Feskanich D., et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med: 2013; 368 4 351 364
14. Pirie K., Peto R., Reeves G. K., Green J., Beral V.; Million Women Study Collaborators. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet: 2013; 381 9861 133 141
15. Lubin J. H., Blot W. J. Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst: 1984; 73 2 383 389 (Pubitemid 14055218)
16. Brownson R. C., Chang J. C., Davis J. R. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology: 1992; 3 1 61 64
17. Risch H. A., Howe G. R., Jain M., Burch J. D., Holowaty E. J., Miller A. B. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol: 1993; 138 5 281 293 (Pubitemid 23263599)
18. Schoenberg J. B., Wilcox H. B., Mason T. J., Bill J., Stemhagen A. Variation in smoking-related lung cancer risk among New Jersey women. Am J Epidemiol: 1989; 130 4 688 695 (Pubitemid 19240197)
19. Osann K. E., Anton-Culver H., Kurosaki T., Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer: 1993; 54 1 44 48 (Pubitemid 23136997)
20. Harris R. E., Zang E. A., Anderson J. I., Wynder E. L. Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol: 1993; 22 4 592 599 (Pubitemid 23247558)
21. Zang E. A., Wynder E. L. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst: 1996; 88 3-4 183 192 (Pubitemid 26065830)
22. McDuffie H. H., Klaassen D. J., Dosman J. A. Female-male differences in patients with primary lung cancer. Cancer: 1987; 59 10 1825 1830 (Pubitemid 17075432)
23. Prescott E., Osler M., Hein H. O., et al. The Copenhagen Center for Prospective Population Studies. Gender and smoking-related risk of lung cancer. Epidemiology: 1998; 9 1 79 83 (Pubitemid 28030495)
24. Kreuzer M., Boffetta P., Whitley E., et al. Gender differences in lung cancer risk by smoking: a multicentre case-control study in Germany and Italy. Br J Cancer: 2000; 82 1 227 233 (Pubitemid 30008986)
25. Halpern M. T., Gillespie B. W., Warner K. E. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst: 1993; 85 6 457 464 (Pubitemid 23084090)
26. Bach P. B., Kattan M. W., Thornquist M. D., et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst: 2003; 95 6 470 478 (Pubitemid 36432421)
27. Bain C., Feskanich D., Speizer F. E., et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst: 2004; 96 11 826 834 (Pubitemid 38807603)
28. De Matteis S., Consonni D., Pesatori A. C., et al. Are women who smoke at higher risk for lung cancer than men who smoke? Am J Epidemiol: 2013; 177 7 601 612
29. Thun M. J., Hannan L. M., Adams-Campbell L. L., et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med: 2008; 5 9 e185
30. Wakelee H. A., Chang E. T., Gomez S. L., et al. Lung cancer incidence in never smokers. J Clin Oncol: 2007; 25 5 472 478 (Pubitemid 350002951)
31. Chiba I., Takahashi T., Nau M. M., et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene: 1990; 5 10 1603 1610
32. Takahashi T., Takahashi T., Suzuki H., et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene: 1991; 6 10 1775 1778 (Pubitemid 21924008)
33. Kure E. H., Ryberg D., Hewer A., et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis: 1996; 17 10 2201 2205 (Pubitemid 26372059)
34. Guinee D. G. Jr, Travis W. D., Trivers G. E., et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis: 1995; 16 5 993 1002
35. Toyooka S., Tsuda T., Gazdar A. F. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat: 2003; 21 3 229 239 (Pubitemid 36292965)
36. Whibley C., Pharoah P. D., Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer: 2009; 9 2 95 107
37. Ahrendt S. A., Decker P. A., Alawi E. A., et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer: 2001; 92 6 1525 1530 (Pubitemid 32947838)
38. Nelson H. H., Christiani D. C., Mark E. J., Wiencke J. K., Wain J. C., Kelsey K. T. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst: 1999; 91 23 2032 2038
39. Aaronson S. A. Growth factors and cancer. Science: 1991; 254 5035 1146 1153 (Pubitemid 21917439)
40. Siegfried J. M., DeMichele M. A., Hunt J. D., Davis A. G., Vohra K. P., Pilewski J. M. Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells. Association with prolonged tobacco exposure and responsiveness to bombesin-like peptides. Am J Respir Crit Care Med: 1997; 156 2 Pt 1 358 366 (Pubitemid 27351965)
41. Ohki-Hamazaki H., Iwabuchi M., Maekawa F. Development and function of bombesin-like peptides and their receptors. Int J Dev Biol: 2005; 49 2-3 293 300 (Pubitemid 40917351)
42. Cuttitta F., Carney D. N., Mulshine J., et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature: 1985; 316 6031 823 826 (Pubitemid 15003742)
43. Leyton J., Garcia-Marin L. J., Tapia J. A., Jensen R. T., Moody T. W. Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells. Cancer Lett: 2001; 162 1 87 95
44. Shriver S. P., Bourdeau H. A., Gubish C. T., et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst: 2000; 92 1 24 33 (Pubitemid 30082225)
45. Scagliotti G. V., Selvaggi G., Novello S., Hirsch F. R. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res: 2004; 10 12 Pt 2 4227s 4232s (Pubitemid 38812451)
46. Paez J. G., Jänne P. A., Lee J. C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science: 2004; 304 5676 1497 1500 (Pubitemid 38720929)
47. Rosell R., Moran T., Queralt C., et al. Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med: 2009; 361 10 958 967
48. Pellegrini C., Falleni M., Marchetti A., et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res: 2003; 9 10 Pt 1 3645 3652 (Pubitemid 37169230)
49. Hirsch F., Veve R., Varella-Garcia M. Evaluation of Her2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization [abstract]. Proc Am Soc Clin Oncol: 2000; 19 486a
50. Hsieh C. C., Chow K. C., Fahn H. J., et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg: 1998; 66 4 1159 1163, discussion 1163-1164
51. Nakachi K., Imai K., Hayashi S., Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res: 1993; 53 13 2994 2999 (Pubitemid 23210302)
52. Gonzalez F. J., Crespi C. L., Gelboin H. V. DNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutat Res: 1991; 247 1 113 127
53. Hecht S. S. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst: 1999; 91 14 1194 1210 (Pubitemid 29357186)
54. Seidegård J., Pero R. W., Markowitz M. M., Roush G., Miller D. G., Beattie E. J. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis: 1990; 11 1 33 36 (Pubitemid 20050732)
55. Mollerup S., Ryberg D., Hewer A., Phillips D. H., Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res: 1999; 59 14 3317 3320 (Pubitemid 29334483)
56. Spitz M. R., Wei Q., Dong Q., Amos C. I., Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev: 2003; 12 8 689 698 (Pubitemid 36993157)
57. Kriek E., Rojas M., Alexandrov K., Bartsch H. Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk. Mutat Res: 1998; 400 1-2 215 231 (Pubitemid 28440224)
58. Peluso M., Munnia A., Hoek G., et al. DNA adducts and lung cancer risk: a prospective study. Cancer Res: 2005; 65 17 8042 8048 (Pubitemid 41297286)
59. Gorlova O. Y., Weng S. F., Zhang Y., Amos C. I., Spitz M. R., Wei Q. DNA repair capacity and lung cancer risk in never smokers. Cancer Epidemiol Biomarkers Prev: 2008; 17 6 1322 1328
60. Ryberg D., Hewer A., Phillips D. H., Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res: 1994; 54 22 5801 5803 (Pubitemid 24375208)
61. Wei Q., Cheng L., Amos C. I., et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst: 2000; 92 21 1764 1772
62. Cheng Y. W., Hsieh L. L., Lin P. P., et al. Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ Mol Mutagen: 2001; 37 4 304 310
63. Stabile L. P., Davis A. L., Gubish C. T., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor. α and β and show biological responses to estrogen. Cancer Res: 2002; 62 7 2141 2150
64. Yager J. D., Liehr J. G. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol: 1996; 36 203 232 (Pubitemid 26168699)
65. Losordo D. W., Isner J. M. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol: 2001; 21 1 6 12 (Pubitemid 32061922)
66. Gao Y. T., Blot W. J., Zheng W., et al. Lung cancer among Chinese women. Int J Cancer: 1987; 40 5 604 609 (Pubitemid 18003846)
67. Taioli E., Wynder E. L. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst: 1994; 86 11 869 870
68. Weiss J. M., Lacey J. V. Jr, Shu X. O., et al. Menstrual and reproductive factors in association with lung cancer in female lifetime nonsmokers. Am J Epidemiol: 2008; 168 11 1319 1325
69. Baik C. S., Strauss G. M., Speizer F. E., Feskanich D. Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev: 2010; 19 10 2525 2533
70. Brinton L. A., Gierach G. L., Andaya A., et al. Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev: 2011; 20 5 900 911
71. Adami H. O., Persson I., Hoover R., Schairer C., Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer: 1989; 44 5 833 839 (Pubitemid 20007980)
72. Schabath M. B., Wu X., Vassilopoulou-Sellin R., Vaporciyan A. A., Spitz M. R. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res: 2004; 10 1 Pt 1 113 123 (Pubitemid 38114169)
73. Greiser C. M., Greiser E. M., Dören M. Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis. Maturitas: 2010; 65 3 198 204
74. Chlebowski R. T., Schwartz A. G., Wakelee H., et al. Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet: 2009; 374 9697 1243 1251
75. Hulley S., Furberg C., Barrett-Connor E., et al. HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA: 2002; 288 1 58 66 (Pubitemid 34705519)
76. Pesatori A. C., Carugno M., Consonni D., et al. Reproductive and hormonal factors and the risk of lung cancer: the EAGLE study. Int J Cancer: 2013; 132 11 2630 2639
77. Levin E. R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol: 2003; 17 3 309 317 (Pubitemid 36315626)
78. Garon E. B., Pietras R. J., Finn R. S., et al. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol: 2013; 8 3 270 278
79. Siegfried J. M., Gubish C. T., Rothstein M. E., Henry C., Stabile L. P. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol: 2012; 7 3 485 495
80. Shen H., Yuan Y., Sun J., Gao W., Shu Y. Q. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother: 2010; 64 2 88 92
81. Chang Y. H., Huang H. D., Shiau M. Y., et al. The correlation of IL-6 and MCL-6 expression in human papilloma virus 16/18 infected lung cancer. Proc Int Assoc Stud Lung Cancer: 2003; 41 02 S119
82. Hennig E. M., Suo Z., Karlsen F., Holm R., Thoresen S., Nesland J. M. HPV positive bronchopulmonary carcinomas in women with previous high-grade cervical intraepithelial neoplasia (CIN III). Acta Oncol: 1999; 38 5 639 647 (Pubitemid 29333747)
83. Cheng Y. W., Chiou H. L., Sheu G. T., et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res: 2001; 61 7 2799 2803
84. Gorgoulis V. G., Zacharatos P., Kotsinas A., et al. Human papilloma virus (HPV) is possibly involved in laryngeal but not in lung carcinogenesis. Hum Pathol: 1999; 30 3 274 283 (Pubitemid 29125146)
85. Welt A., Hummel M., Niedobitek G., Stein H. Human papillomavirus infection is not associated with bronchial carcinoma: evaluation by in situ hybridization and the polymerase chain reaction. J Pathol: 1997; 181 3 276 280 (Pubitemid 27156839)
86. Greenberg E. R., Korson R., Baker J., Barrett J., Baron J. A., Yates J. Incidence of lung cancer by cell type: a population-based study in New Hampshire and Vermont. J Natl Cancer Inst: 1984; 72 3 599 603 (Pubitemid 14161156)
87. Thun M. J., Lally C. A., Flannery J. T., Calle E. E., Flanders W. D., Heath C. W. Jr. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst: 1997; 89 21 1580 1586 (Pubitemid 27479717)
88. Stellman S. D., Muscat J. E., Thompson S., Hoffmann D., Wynder E. L. Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking. Cancer: 1997; 80 3 382 388 (Pubitemid 27323407)
89. Barkley J. E., Green M. R. Bronchioloalveolar carcinoma. J Clin Oncol: 1996; 14 8 2377 2386 (Pubitemid 26264891)
90. Albertine K. H., Steiner R. M., Radack D. M., et al. Analysis of cell type and radiographic presentation as predictors of the clinical course of patients with bronchioalveolar cell carcinoma. Chest: 1998; 113 4 997 1006 (Pubitemid 28216445)
91. Travis W. D., Brambilla E., Noguchi M., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol: 2011; 6 2 244 285
92. Alterkrouse S. F., Kosary C. L., Krapcho M., et al. SEER Cancer Statistics Review 1975-2010. National Cancer Institute. http://seer.cancer.gov. Posted SEER web site April: 2013
93. Schoenberg J. B., Wilcox H. B., Mason T. J., Bill J., Stemhagen A. Variation in smoking-related lung cancer risk among New Jersey women. Am J Epidemiol: 1989; 130 4 688 695 (Pubitemid 19240197)
94. Ramalingam S., Pawlish K., Gadgeel S., Demers R., Kalemkerian G. P. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol: 1998; 16 2 651 657 (Pubitemid 28135612)
95. Fu J. B., Kau T. Y., Severson R. K., Kalemkerian G. P. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest: 2005; 127 3 768 777 (Pubitemid 40775504)
96. Radzikowska E., Głaz P., Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol: 2002; 13 7 1087 1093
97. Asamura H., Goya T., Koshiishi Y., et al. Japanese Joint Committee of Lung Cancer Registry. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol: 2008; 3 1 46 52
98. Mitsudomi T., Tateishi M., Oka T., Yano T., Ishida T., Sugimachi K. Longer survival after resection of non-small cell lung cancer in Japanese women. Ann Thorac Surg: 1989; 48 5 639 642 (Pubitemid 19270431)
99. Minami H., Yoshimura M., Miyamoto Y., Matsuoka H., Tsubota N. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest: 2000; 118 6 1603 1609 (Pubitemid 32001783)
100. Ferguson M. K., Wang J., Hoffman P. C., et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg: 2000; 69 1 245 249, discussion 249-250
101. Cerfolio R. J., Bryant A. S., Scott E., et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest: 2006; 130 6 1796 1802 (Pubitemid 46033436)
102. Movsas B., Bac K., Langer C. J., et al. The influence of gender, race, and/or marital status on survival in lung cancer patients: meta-analysis of radiation therapy oncology group (RTOG) trials. J Thorac Oncol: 2010; 5 5 631 9
103. O'Connell J. P., Kris M. G., Gralla R. J., et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol: 1986; 4 11 1604 1614 (Pubitemid 17188927)
104. Albain K. S., Crowley J. J., LeBlanc M., Livingston R. B. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol: 1990; 8 9 1563 1574 (Pubitemid 20301188)
105. Videtic G. M., Reddy C. A., Chao S. T., et al. Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the Radiation Therapy Oncology Group recursive partitioning analysis classification. Int J Radiat Oncol Biol Phys: 2009; 75 4 1141 1147
106. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol: 2003; 21 12 2237 2246 (Pubitemid 46621858)
107. Kris M. G., Natale R. B., Herbst R. S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA: 2003; 290 16 2149 2158 (Pubitemid 37432975)
108. Shepherd F. A., Rodrigues Pereira J., Ciuleanu T., et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med: 2005; 353 2 123 132 (Pubitemid 41058344)
109. Lynch T. J., Bell D. W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med: 2004; 350 21 2129 2139 (Pubitemid 38637993)
110. Sekine I., Sumi M., Ito Y., et al. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy. Jpn J Clin Oncol: 2009; 39 11 707 712
111. Ganti A. K., Sahmoun A. E., Panwalkar A. W., Tendulkar K. K., Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol: 2006; 24 1 59 63 (Pubitemid 46630494)
112. Chlebowski R. T., Anderson G. L., Manson J. E., et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst: 2010; 102 18 1413 1421